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A bstract. Patients with familial hypen:ho1es-
terolemia have elevated levels of plasma low density li-
poproteins (LDL), increased hepatic synthesis of apoli-
poprotein B-containing lipoproteins, defective binding of 
low density lipoproteins to fibroblasts, and premature 
atherosclerosis. The role of a hepatic low density lipo-
protein receptor in normal man and its importance in 
the pathogenesis of familial hypercholesterolemia have 
not been previously determined. In the present study, 
direct comparison was made of the binding of LDL to 
hepatic membranes from normal and receptor-negative 
homozygous familial hypercholesterolemic subjects. The 
effects of calcium, EDT A, and temperature on the binding 
of lipoproteins to the hepatic membranes were also eval-
uated. At 4°e, no significant difference in specific binding 
of LDL to hepatic membranes from normal and familial 
hypercholesterolemic subjects was observed. At 3rC, 
both total and specific binding of LDL were significantly 
reduced in patients with familial hypercholesterolemia. 
Hepatic membrane binding ofLDL from the two patients 
homozygous for receptor-negative familial hypercholes-
terolemia was 53 and 59% of normal. The activity of the 
rate-limiting enzyme in cholesterol biosynthesis, 3-hy-
droxy-3-methylglutaryl coenzyme A reductase was nor-
mal; however, the total hepatic cholesterol and cholesteryl 
ester content was significantly increased from 53 to 129%. 
A preliminary account of this work was presented at the American 
Federation for Clinical Research Meetings held in Washington DC May 
1982. 
Received for publication 9 September 1982 and in revised fiJrm 4 
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- ------------
The Journal of Clinical Investigation, Inc. 
Volume 73, February 1984,429-436 
Characterization of Hepatic 
Low Density Lipoprotein Binding 
and Cholesterol Metabolism in Normal 
and Homozygous Familial 
Hypercholesterolemic Subjects 
Jeffrey M. Hoeg, Stephen J. Demosky, Jr., 
Ernst J. Schaefer, Thomas E. Starzl, 
and H. Bryan Brewer, Jr. 
Molecular Disease Branch. National Heart. Lung. and Blood 
Institute. National Institutes of Health. Bethesda. Maryland 
20205: The University E~f Pittsburgh School of Medicine. 
Pittsburgh. Pennsylvania 15260 
These results indicate that patients with familial hyper-
cholesterolemia have a defect in the interaction of hepatic 
membranes with low density lipoproteins. This defect 
may lead to accelerated atherosclerosis by decreasing the 
cellular catabolism of LDL and enhancing the production 
of LDL, which is characteristic of patients homozygous 
for familial hypercholesterolemia. 
Introduction 
Familial hypercholesterolemia (FH)I is an autosomal co-dom-
inant disorder characterized clinically by hypercholesterolemia, 
xanthomas, and premature atherosclerosis (I). In vitro study of 
skin fibroblasts from patients homozygous for FH revealed that 
the disorder is caused by one of several mutations in the gene 
coding for the cellular receptor for low density lipoproteins 
(LDL) (2, 3). This LDL receptor normally binds LDL, which 
is then internalized and degraded in the Iysosomes, and provides 
cholesterol for use in cellular metabolism (4). Fibroblasts from 
patients homozygous for FH who have the most frequent allelic 
mutation have no functional receptors and are referred to as 
receptor-negative (3). Therefore, it is thought that when the 
receptor is functionally absent, LDL is not degraded at a normal 
rate and plasma LDL concentration increases. 
The liver plays a central role in cholesterol and lipoprotein 
metabolism (5-7). Endogenous cholesterol synthesis occurs in 
the liver and the precursor to plasma LDL, very low density 
lipoproteins (VLDL), are synthesized and secreted by the liver 
(5, 8). Moreover, recent studies, in rats, mice, dogs, and rabbits 
have demonstrated specific binding of LDL to the liver (9-13). 
The physiologic role of such LDL-hepatic interaction in man 
and the pathophysiologic significance ofLDL-hepatic interaction 
I. Abbreviations used in this paper: FH, familial hypercholesterolemia; 
HMG-CoA, 3-hydroxy-3-methylgJutaryl coenzyme A reductase; LPDS, 
lipoprotein-deficient serum; TrisCI, Tris (hydroxymethyl) aminomethane. 
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in FH has been previously unknown. The current studies were 
designed to quantitate hepatic LDL membrane binding, cho-
lesterol/cholesteryl ester content, and 3-hydroxy-3-methylglu-
aryl coenzyme A (HMO-CoA) reductase activity in normal 
subjects and FH patients. 
Methods 
Patients. Subjects from two unrelated kindreds were evaluated by phy-
sicians of the Molecular Disease Branch of the National Heart, Lung, 
and Blood Institute at the Clinical Center of the National Institutes of 
Health in Bethesda, MD. The clinical data from these patients are sum-
marized in Table I. The clinical diagnosis of FH was based on the 
presence of hypercholesterolemia, tendon xanthomas, premature ath-
erosclerosis, plasma LDL cholesterol in excess of two standard deviations 
of the mean normal levels for age and sex, and an inheritance pattern 
consistent with the diagnosis (I). Skin biopsies for fibroblast studies were 
obtained from normolipidemic volunteers and the two patients ho-
mozygous for this disease (D.P., T.H.). Liver biopsies were performed 
on normolipidemic renal transplant donors (ages 21,27,32, and 36 yr) 
and from D.P. and T.H. at the time of portacaval shunt of the liver for 
treatment of these patients' conditions after obtaining informed consent. 
The liver biopsy protocol was approved by the Human Experimentations 
Committee at the University of Pittsburgh, where the biopsies were 
performed. 
Lipoprotein isolation. Human LDL (d 1.030-1.050 g/ml) and li-
poprotein-deficient serum (d < 1.215 g/ml) were prepared from 500 ml 
plasma collected in 0.0 I % EDTA by plasmapheresis from fasting, healthy 
volunteers. Lipoproteins were separated by preparative ultracentrifugation 
at 4°C for 16-24 h (14) using K3r for density-gradient adjustment 
(15). These subfractions were then dialyzed 34 h at 4°C against 150 vol 
of phosphate-buffered saline (PBS) (pH 7.0) (Gihco Laboratories, Grand 
Island, NY). After dialysis, Iipoprotein .. deficient serum (LPDS) was de-
fibrinated with thrombin (Park, Davis and Co., Detnit, MI). Each isolated 
lipoprotein fraction was sterilized by 0.45-ILm Millipore filtration (Mil-
lipore Corp., Bedford, MA) and used within I mo of preparation. 1251_ 
LDL was prepared by the iodine monochloride method (16) as modified 
for lipoproteins (17). A 25-30% efficiency of iodination was obtained 
and <6% of the radioactivity was soluble in the organic phase following 
a chloroform-methanol extraction. After ('ialysis over 24 h at 4°C against 
500-600 vol PBS, speCific activities ranged from 2.7 to 4.6 X 109 Bec-
querels/mg LDL protein. The concentration of LDL is expressed in 
terms of its protein content using bovine serum albumin standard as 
determined by the method of Lowry et al. (18). After Millipore filtration, 
1251_LDL was stored at 4°C and used within 2-3 wk of preparation. 
LDL used for competition assays was modified by acetoacetylation as 
described by Mahley et al. (19). 
Fibroblast preparation. The fibroblasts used in these studies were 
established from explants of skin obtained from the study subjects by 
punch bivpsy. All cell lines were grown in monolayer and used after 
three to seven passages. Cell lines were maintained in a humidified 
incubator at 37°C in a 5% CO2 atmosphere in 150-cm2 sterile flasks 
(Costar, Cambridge, MA). Eagles minimal essential medium was sup-
plemented by 2 mM glutamine (Gibco Laboratories) and 10% (vol/vol) 
fetal calf serum (Sterile Systems, Inc., Logan. UTi. For the 1251_LDL 
experiments, I X 105 cells were harvested on day 0 with 0.05% trypsin-
0.05% EDTA and placed in 30-mm petri dishes (Costar). On days I, 
3, and 5 the media was re1Jlaced with fresh growth media supplemented 
with 10% (vol/vol) fetal calf serum. On day 6, when cells were still 
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preconfluent (4-6 X 105 cells/plate), the media was replaced with 3 ml 
of fresh media containing 10% (vol/vol) LPDS (final protein concen-
tration, 2.5 mg/ml). For the HMG-CoA reductase assays, 2 X 106 tryp-
sinized fibroblasts were added to 10 ml of media containing 10% (vol/ 
vol) LPDS in 100-mm petri dishes (Falcon Labware, Oxnard, CAl. The 
10% LPDS media was replaced 24 h after initial seeding. After 36 h of 
incubation in 10% LPDS media, cells were prepared for assay ofHMG-
CoA reductase activity. 
Liver memhrane preparation. Biopsy specimens were immediately 
placed in a beaker and all processing occurred at 4°C (20, 21). After 
mincing the tissue with a razor blade, it was washed with an ice-cold 
buffer containing 0.9% (vol/vol) NaCl, I mM EDTA, 10 mM Tris (hy-
droxymethyl) aminomethane (TrisCI) (pH 8.0). Homogenization was 
performed by six strokes of a motor-driven Teflon pestle in a buffer 
containing 0.25 M sucrose, I mM EDTA, and 10 mM TrisCI (pH 8.0). 
The homogenized preparations ( 10 mg/ml) were centrifuged for 10 min 
at 1,000 g. The supernatant solution was recentrifuged for 25 min at 
10,000 g, followed by ultracentrifugation at 100,000 g for 60 min. The 
pellet from this ultracentrifugation was resuspended in a buffer containing 
150 mM NaC!, 10 mM TlisCI (pH 8.0), and flushed through a 22-gauge 
needle 10 times. These membranes were recentrifuged for IS min at 
100,000 g and the membrane pellets were then frozen in dry ice and 
stored in liquid nitrogen until they were used for binding assays and 
measurement of HMG-CoA reductase activity. 
HMG-CoA reductase assay. Cells and hepatic membranes were pre-
pared as described above and fibroblasts were incubated for 36 h in 10% 
LPDS. The media was then replaced by 10% LPDS containing one of 
the following concentrations of LDL protein: 5, 15, 25, 50, 75, or 100 
Ilg/ml. After 6 h of incubation with LDL, cells were washed four times 
with 2 ml of ice-cold PBS (pH 7.0) and scraped with a rubber policeman. 
The contents of duplicate 100-mm petri dishes were then pooled and 
centrifuged for 20 min at 4°C. The supernatant was decanted and cell 
pellets frozen in dry ice. Cell pellets from both fibroblasts as well as 
liver membranes were then stored in liquid nitrogen until HMG-CoA 
reductase activity was quantitated. All assays were performed within 4 
d of cell harvesting and repetitive studies indicated no loss of HMG-
CoA reductase activity over this time period. The HMG-CoA reductase 
assay used was modified from that described by Beg et a!. (22). Cell 
pellets were thawed slowly to room temperature and then subjected to 
membrane dissolution with 200 III 0.1 M KH2P04 , I mM EDTA, 10 
mM KCI, and 4 mM 3-[(3-cholamidopropyl)dimethyl-ammonioJ-l-
propane-sulfonate-2 H20 (Calbiochem-Behring Corp., La Jolla, CA.) at 
pH 7.5. After a IO-min, 4°C incubation, 45 III of this fractionated cell 
suspension was added to 125 III of substrate buffer (0.16 M KH2PO., 
67 mM EDTA, 5 mM dithiothreitol, and 10 mM NADPH, at pH 7.0). 
[3HJMevalonic acid (New England Nuclear, Boston, MA) was added to 
each sample for internal standardization. Unlabeled HMG-CoA was 
added to d,l-[3-!4C)HMG-CoA (New England Nuclear) to produce a 
final specific activity of 4.92 X 108 Bequerels (dps)/mM. The final assay 
volume was adjusted to 200 ILl by the addition of 30 ILl of d,/-[ 3..14C)-
HMG-CoA. Incubation was carried out for 30 min in a 37°C shaker 
bath. The reaction was terminated by the addition of 40 III of 10 N HCI 
followed by a I-min centrifugation in a microfuge B (Beckman Instru-
ments, Inc., Palo Alto, CAl. The final labeled product, [I4C)mevalonic 
acid, was isolated by applying 120 III of the incubation supernatant to 
a I ml Bio-Rex 5, 100-200 mesh anion-exchange column (Bio-Rad 
Laboratories, Richmond, CAl. The isolated [!4C)mevalonate was quan-
tified in a liquid scintillation system Mark III (Searle Analytic, Inc., 
Skokie, IL). The quantity of protein in each incubation was determined 
by the method of Lowry et al. (18) and HMG-CoA reductase activity 
was expressed as disintegrations per minute per milligram of protein. 
The amount of protein per sample ranged from 100 to 200 J.Lg and all 
assays were performed in the linear range. 
Binding oF251-LDL to liver membranes. The frozen liver membrane 
preparations were thawed and resuspended through a 22-gauge needle 
in a 50 mM NaCI. 30 mM TrisC! (pH 7.5) buffer to a membrane protein 
concentration of 10-12 mg/m\. Membranes were then sonicated by five 
4-s pulses at the 55-W setting, using an Ultrasonics microtip (Heat 
Systems Ultrasonics, Inc., Plainview, NY). From 100 to 200 J.Lg membrane 
protein suspended in a buffer containing 75 mM NaC!, 150 mM TrisCI 
(pH 7.5) was then added to a 50 mM NaC!, 20 mM TrisCI (pH 7.5) 
buffer containing either I mM CaCI2 or 30 mM EDT A. 1251_LDL was 
added at the concentrations indicated in the respective Tables and Figure 
legends with or without unlabeled LDL to a total assay mixture volume 
of 0.1 ml. Incubations were carried out at 0° or 37"C for 30 min. Bound 
125I_LDL was separated from free ligand by a 3-min, 100,000 g cen-
trifugation of 50 J.LI of the assay mixture through 125 J.Ll PBS in a 30°-
angle rotor in an air-driven ultracentrifuge (Beckman Instruments, Inc.). 
The supernatant was removed from the pellet by vacuum aspiration, 
and the pellet was washed once with 125 Iii of PBS. The cellulose nitrate 
tube tips containing the membrane pellet were sliced and the radioactivity 
in the pellet quantified in a Biogamma II scintillation counter (Bcckman 
Instruments, Inc.). Specifically bound "'I-LDL was defined as the dif-
ference in 1251_LDL quantitated in samples that were incubated with 
and without 3,900-4,600 J.Lg/ml of unlabeled LDL. Competition binding 
experiments were conducted by assessing the specific 125I_LDL binding 
in the presence of the indicated concentrations of unlabeled LDL, ace-
toacetylated LDl. or asialofetuin. 
Lipoprotein quantilation. Blood was obtained in 0.1 % EDT A from 
subjects after a 12- to 14-h overnight fast, and the plasma was separated 
Table I. Summary of Clinical Data 
Plasma cholesterol 
SUhject Position Age Sex Total LDL VLDL HDL 
----
Kindred I 
H.P. Father 37 M 348 284 42 23 
S.P. Mother 35 F 353 263 54 36 
D.P. Son 7 M 849 810 37 2 
M.P. Daughter 8 F 362 288 34 40 
Kindred 2 
B.H. Mother 42 F 462 359 82 21 
T.H. Daughter 21 F 908 843 52 13 
at 4°C in a refrigerated centrifuge. Plasma cholesterol and triglycerides 
were quantitated with an Autoanalyzer II (Technicon Instruments Corp., 
Tarrytown, NY) (23). High density lipoprotein (HDL) cholesterol was 
measured after heparin manganese precipitation in plasma (24). Plasma 
was ultracentrifuged at d < 1.006 g/ml for 18 h at 39,000 rpm (4°C) 
in 40.3 rotors (Beckman Instruments, Inc.), and the VLDL was separated 
from the other plasma lipoproteins by tube slicing (14). The cholesterol 
concentration in the 1.006 glml infranate was measured, and the VLDL 
and LDL cholesterol were calculated (22). 
Hepatic cholesterol and cholesteryl ester determination. Liver biopsy 
samples from three normal subjects, patient D.P., and patient T.H. were 
weighed, extracted three times with chloroform/methanol (2: I vOl/vol; 
60-240 mg/ml) at 41 0e. This extraction was followed by an overnight 
extraction with chloroform/methanol (2: 1, vol/vol) at 30°e. The chlo-
roform/methanol was blown to dryness and the liquid was resuspended 
in 2-propanol (J. T. Baker Chemical Co., Phillipsburg, NJ). Free and 
total cholesterol were then measured by the enzymic, fluorimetric method 
of Heider and Boyette (25). Esterified cholesterol was determined as the 
difference between total and free cholesterol. The nanomoles of cholesterol 
extracted from the biopsy samples were then normalized to the initial 
sample weight. 
Results 
Patient clinical data. The clinical data of the patients from the 
two kindreds that were evaluated are summarized in Table I. 
These data were consistent with the clinical diagnosis of FH. 
Despite the use of a hypocholesterolemic diet and a variety of 
drugs, the levels of total plasma cholesterol and LDL cholesterol 
Plasma Lipid lowering 
triglycerides treatment Disease Diagnosis 
- ----- ---------
mgjdl 
345 Niacin neomycin Angina FH heterozygote 
colestipol CABG* 
218 Colestipol Carotid Bruit FH heterozygote 
258 Neomycin Bilateral FH homozygote 
Femoral 
Bruits 
88 Diet None FH heterozygote 
Evident 
414 Clofibrate MIt, CABG* FH heterozygote 
Deceased 
222 Niacin Angina MIt FH homozygote 
cholcstyramine CABG* 
------- - --------
* CABG, coronary artery bypass graft. t MI, documented myocardial infarction. 
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were strikingly elevated in heterozygotes as well as homozygotes. 
Total plasma cholesterol for heterozygotes ranged from 348 to 
462 mg/dl and homozygotes had approximately double these 
values at 849 and 908, despite therapeutic trials of a variety of 
agents. 
Fibroblast HMG-CoA reductase activity. The LDL receptor 
status was determined by studies performed on fibroblasts from 
these two homozygous patients. First, the ability of LDL to 
suppress the activity of the rate-limiting enzyme for cellular 
cholesterol synthesis, HMG-CoA reductase, was assessed in nor-
mal fibroblasts and in fibroblasts from D.P. and T.H. (Fig. I). 
As little as 10 Itg/ml of LDL protein in the media suppressed 
the activity of HMG-CoA reductase by >60% in normal fibro-
blasts. There was a progressive decrease in HMG-CoA reductase 
activity with increasing concentrations of LDL in the media in 
normal cells. In fibroblasts from D.P. and T.H., on the other 
hand, increasing concentrations of LDL had no effect on the 
activity ofHMG-CoA reductase. Even 100 Itg/ml ofLDL protein 
did not reduce the activity of this enzyme below that seen in 
the cells grown in the absence of LDL in the media. In addition, 
using their immunoblotting technique, Beisiegel et al. (26) found 
no LDL receptors in fibroblasts from these patients. Thus, these 
two individuals have been designated as receptor-negative FH. 
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Figure 1. The effect of LDL on the HMG-CoA reductase activity of 
fibroblasts from normal and familial hypercholesterolemic subjects. 
Preconfluent fibroblasts from a normal subject (e), T.H. (0), and 
D.P. ( ... ) were incubated 36 h in 10% LPDS media. Media was re-
placed with the indicated concentrations of LDL and the cells were 
then incubated for 6 h at 37°C. After extensive washing, cells were 
harvested with a rubber policeman, pelleted, and frozen. After solubi-
lization of the cells, the conversion of [I4C)HMG-CoA to 
[l4C)mevalonate was measured after a 30 min, 37°C incubation and 
corrected for total cellular protein. The normal activity of fibroblasts 
not exposed to LDL, used as 100% activity, was 216 pmol/mg cellu-
lar protein. The activity of HMG-CoA reductase is expressed as the 
percentage of activity observed in the absence of LDL. Values repre-
sent the mean of duplicate plates. 
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Figure 2. The effect of incubation temperature, calcium, EDT A, and 
excess unlabeled LDL on the binding of '25I_LDL to adult human 
hepatic membranes. From 138 to 182 p.g of hepatic membranes were 
added to a 75 mM NaCl, 150 mM TrisCI buffer containing I mM 
CaCh (e), 30 mM EDTA (0) or 20-fold excess unlabeled LDL ( ... ). 
These mixtures were then incubated for 30 min at the indicated con-
centrations of 125I_LDL at either O°C (A and B) or 37°C (C and D). 
Total specific binding (_) and EDTA sensitive binding (0) were the 
differences between the binding observed in the absence and presence 
of unlabeled LDL and between the binding observed in I mM CaCb 
and 30 mM EDTA, respectively. Values represent the mean±SE of 
triplicate samples. 
Binding of 125/_LDL to adult human hepatic membranes. 
The ability of hepatic membranes isolated from the study subjects 
to bind 125I_LDL was assessed. The effects of incubation tem-
perature, calcium, and a 20-fold excess of LDL on this 125 1_ 
LDL-membrane interaction are summarized in Fig. 2. Total, 
EDT A resistant, and nonspecific 125I_LDL binding were all much 
lower during the O°C incubation (Fig. 2 A) than observed at 
37°C (Fig. 2 C) with a two to fourfold increase in binding at 
the higher temperature. The specific '2sl_LDL binding (Fig. 2 
B and D), defined as the difference in binding observed in the 
absence and presence of unlabeled LDL, was quantitatively as 
well as qualitatively different between membranes incubated at 
0° and 37°C. Binding assays conducted at 37°C resulted in not 
only a two to fourfold increase in the specific binding occurring 
at O°C, but also the 3rC binding using a constant 20-fold 
excess unlabeled LDL reached saturation while the O°C binding 
was nonsaturable. Therefore, incubation temperature markedly 
affected not only the degree of 125I_LDL binding, but also the 
saturation characteristics. 
Incubation temperature and 125I_LDL concentration also 
affected the degree of EDT A resistant binding. At O°C (Fig. 2 
B), the calcium-dependent binding, defined as the difference in 
binding observed in the presence of I mM CaCh and 30 mM 
EDT A, initially was 20% of the total specific LDL binding. At 
the SO-ltg/assay 125I_LDL concentration, however, calcium-de-
pendent binding was more often SO% of the total specific binding. 
In contrast, the calcium-dependent binding at 37°C (Fig. 2 D) 
reflected about one-third of specific 125I_LDL binding regardless 
of concentration. Furthermore, the calcium-dependent binding 
at 37°C demonstrated saturability, whereas at O°C there was 
no saturability at the concentrations tested. These observations 
indicate that the binding of 125I_LDL to human hepatic mem-
branes is highly temperature dependent and that at physiologic 
temperature and LOL concentration binding is saturable and 
specific with both calcium-dependent as well as calcium-inde-
pendent characteristics. 
The specificity of LOL-membrane interaction observed at 
37°C was assessed by competitive binding assays of LDL, ace-
toacetylated LOL, and asialofetuin with 125I_LDL (Fig. 3). As 
100 
90 
80 
~ 70 
is 
z 
iii 
...J 
o 
...J 
~ 50 
u 
u:: 
U 40 
w 
0-
(fJ 
...J 
<! 
i= ~ 30 
I-
Z 
w 
U 
'" W 0.. 
20 
10 
.. 
o 
• 
------DRM----------1ioo-----ff"~D--~OMMi---
COMPETITION LIGAND CONCENTRATION 
f~g protein/assay) 
Figure 3. The competition for specific 1251_LDL binding with LDL, 
modified LDL. and asialofetuin. Increasing concentrations of LDL 
(e). acetoacetylated LDL (0). and asialofetuin (.) were incubated 
with 100-200 ~g hepatic membrane protein and 20 ~g 125J_LDL in 
the presence of I mM calcium for 30 min at 37°C. The 100% initial 
specific activity observed was 1.562 ~g 1251_LDL bound/mg mem-
brane protein. 
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Figure 4. Binding of 1251_LDL to hepatic membranes from normal 
and familial hypercholesterolemic SUbjects. Membranes were pre-
pared from hepatic biopsy specimens from three normal subjects (A), 
T.H. (B), and D.P. (C). From 100 to 200 ~g membrane protein was 
added to a 75 mM NaCl, 150 mM TrisCI, 1 mM CaCh (pH 7.5) 
buffer with the indicated concentrations of 1251_LDL in the presence 
and absence of 396 ~g of unlabeled LDL. Specifically bound 1251_ 
LDL (.), defined as the difference in 1251_LDL bound in the presence 
(0) and absence (e) of excess unlabeled LDL, was normalized to the 
amount of membrane protein in the sample. D depicts the specific 
binding observed in normal subjects (e), D.P. (0), and T.H. (.). Val-
ues represent the mean±SE of triplicate determinations. 
little as S Itg of unlabeled LDL reduced 125I_LDL binding by 
SO%. In contrast, the LDL that had undergone modification of 
its lysyl residues by acetoacetylation did not effectively compete 
for the 125I_LDL binding site. 200 Itg of acetoacetylated LDL 
displaced <SO% of specifically bound 125I_LDL. Similarly, asi-
alofetuin displaced little, if any, 125I_LDL. Thus, the 125I_LDL 
was successfully displaced by unlabeled LDL but not acetoacet-
ylated LDL or asialofetuin. 
The effect of increasing concentrations of 125I_LDL on total, 
nonspecific, and specific 125I_LDL binding to normal hepatic 
membranes and membranes from F.H. patients was assessed 
at 37°C in the presence of calcium (Fig. 4). Although there was 
slightly less nonspecific 125I_LDL binding in T.H. and D.P. than 
normal, both the total and specific binding were markedly re-
duced. As seen in Fig. 4 D, from 8 Itg 125I_LDL per assay on, 
the specific binding in both D.P. and T.H. was markedly at-
tenuated. 
Hepatic cholesterol content. The free and esterified cholesterol 
content from the liver of these study subjects was also determined 
(Table II). The total cholesterol content in liver from T.H. and 
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Table II. Cholesterol and Cholesleryl Ester Content of Liver Fum 
Normal and Familial Hypercholesterolemic Subjects· 
--------~~~~ 
Total Free Esterified 
-- - -- ---------
Normal 1 3.23±O.O9 3. 13±0.44 O.10±O.45 
Normal 2 3.24±O.21 3.17±O.20 O.O7±O.29 
Normal 3 3.39±O.13 3.19±O.27 O.20±O.30 
Patient T.H. 5.03±O.24 3.53±O.47 1.50±O.53 
Patient D.P. 7.55±O.53 4.81±O.46 2.74±O.70 
* Values represent the mean±SE of triplicate samples and are ex-
pressed as nanomoles per milligram of wet tissue. 
D.P. was increased by 53 and 129%, respectively. The majority 
of this increase was fou nd in the esterified form of cholesterol. 
The cholesteryl ester content was indistinguishable from zero 
for the three normal controls, but the levels found in D.P. and 
T.H. accounted for over 80% of the increase observed in total 
hepatic cholesterol content. 
Hepatic HMCi-CoA reduclase activity. The HMG-CoA re-
ductase activity from three normal livers was 8.93± 1.22 pmolj 
min per mg protein. Both D.P. and T.H. had comparable levels 
of activity at 87 and 85% of normal. Therefore, there was no 
difference in the activity of this enzyme between livers from 
normal and FH subjects. 
Discussion 
The liver plays a central role in mammalian lipid and lipoprotein 
metabolism. It is the major site for synthesis and secretion of 
apolipoprotein B-containing VLDL, which is the major precursor 
of LDL. In addition, the liver has been demonstrated to be a 
major site of catabolism of an injected dose of labeled LDL 
from the plasma of nonhuman species (27, 28), and hepatic 
recognition site for LDL has been reported in several animal 
studies (9, 10, 12, 13, 2 J, 29). Uptake of LDL by peripheral 
cells such as fibroblasts has been shown to be mediated by a 
well characterized, high-affinity, calcium dependent, saturable 
protein receptor system (30). Several lines of evidence indicate 
that hepatic recognition and uptake of LDL in several animal 
species may be more complex than has been observed for non-
hepatic cell lines. First, Mahley and co-workers (29) evaluated 
high-affinity, calcium-dependent binding to hepatic membranes 
in adult mammalian species, including swine and man. No 
binding resembling that of the classic fibroblasts LDL receptor 
was observed. Secondly, using in vitro porcine hepatocyte cul-
tures, Bachorick et at. (3 J ) have shown that LDL can be bound. 
internalized, and degraded by uptake pathway(s) independent 
of pinocytosis or the classical LDL receptor pathway. These 
lipoprotein recognition site(s) did not resemble the classical LDL 
receptor. Instead, this uptake was best correlated by a lower 
affinity, saturable, specific binding site they had previously iden-
tified in adult porcine hepatic membranes (21). Thus, in the 
adult pig, specific hepatic recognition sites that differ from the 
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characteristics of the classic fibroblasts LDL receptor appeared 
to be of physiologic significance. In contrast, using r4C]sucrose-
labeled LDL, Pittman et al. (28) demonstrated that adult porcine 
hepatocytes avidly bound LDL and delivered it to the lysosomes. 
Our data suggest that as in swine, hepatic LDL recognition 
in man is unlike the classic fibroblast LDL receptor. As previously 
reported by Mahley and co-workers (29), little if any specific 
125I_LDL binding was observed when low LDL concentrations 
and a 0-4°C incubation were used, the conditions classically 
used to determine fibroblast LDL receptors. Moreover, specific 
LDL binding was saturable only when the assay was performed 
at 37°C at physiological concentrations of LDL. Plasma LDL 
cholesterol concentrations in nornlal adults are -100-150 mgj 
100 ml. Since protein represents 20-25% of LDL on a weight 
basis (32), the normal plasma apolipoprotein-LDL concentration 
is - 60 mgj! 00 or 60 ILgjO.! ml. Therefore, the saturable specific 
binding we observed (Fig. 2) at 20-50 ILgjO.1 ml 125I_LDL con-
centration would be anticipated to be more physiologically rel-
evant as a control mechanism than would nonsaturable binding 
observed at one-tenth this concentration. Furthermore, as in 
the swine, the specific saturable LDL binding (Fig. 3) observed 
at 37°C was only partially calcium dependent. Finally, Harders-
Spengel et al. (33) recently reported that adult human mem-
branes did have a small degree of specific, saturable binding at 
low temperatures and LDL concentration. This binding, how-
ever, was also different from that of the classical fibroblast LDL 
receptor in that the binding was largely calcium independent. 
In addition, their reported data are at odds with the virtual 
absence of binding reported by Mahley and co-workers (29). 
Therefore, it appears that the characteristics of the hepatic rec-
ognition site for LDL in man are distinct from the characteristics 
of the "classic" LDL receptor of peripheral tissues, although it 
is specific and saturable. 
By assessing the hepatic membrane recognition of LDL in 
two patients homozygous for receptor-negative FH, we hoped 
to gain further insight into the function(s) of human hepatic 
membrane lipoprotein receptor function. The results obtained 
from the experiments depicted in Fig. 4 were intriguing. As 
depicted by the current concepts on lipoprotein metabolism 
(30), the binding of LDL to hepatic membranes from both FH 
homozygotes was decidedly decreased. This observation agrees 
with the decline in hepatic membrane binding detected in FH 
heterozygotes by Harders-Spengel et al. (33). But unlike the 
theoretic predictions, at least half of the specific LDL binding 
to the FH homozygote membrane remained intact. 
These findings cannot be ascribed to factors such as age or 
prior hypolipidemic therapy. Both younger age (29) and cho-
lestyramine treatment (34) are associated with enhanced rec-
ognition of LDL by canine hepatic membranes. Therefore, the 
decreased binding of LDL observed in the younger, cholestyr-
amine-treated FH subjects in the present study appears even 
more striking. Since no classic fibroblast LDL receptor was 
present in either of these patients, this decreased binding may 
reflect the loss of the LDL receptor gene product as expressed 
in the liver. Moreover, the residual hepatic LDL binding in 
these individuals may represent hepatic receptors that are ge-
netically distinct from the classic LDL receptor. Recognition 
sites for apolipoprotein E, apolipoprotein B-48, apolipoproteins 
A-II A-II, or even a recognition site for some moiety other than 
an apolipoprotein, which to some extent interact specifically 
with LDL, could result in LDL residual binding observed in 
these studies. 
The residual binding observed in the homozygote hepatic 
membranes of FH homozygotes is consistent with a number of 
observations previously made in patients with FH as well as in 
the animal model for this disease, the Watanabe Heritable Hy-
perlipidemic (WHHL) rabbit. Firstly, the fractional catabolic 
rate of an injected dose of 125I_LDL is reduced in FH homo-
zygotes when compared with normals (35-38), however, the 
total quantity of LDL catabolized from the plasma is markedly 
elevated. The residual hepatic membrane binding observed in 
our FH homozygotes could provide for this LDL clearance in 
FH subjects. In addition, direct determination of LDL binding 
to hepatic membranes ofWHHL rabbits demonstrated no classic 
LDL receptors (39). Despite this loss of the classic LDL receptor, 
['4C]sucrose-labeled LDL was bound and internalized by the 
liver in these animals (40). As in normal rabbits, over half an 
injected dose of LDL was removed by the liver in the WHHL 
rabbits. This uptake appears to be independent of both the 
classic LDL as well as pinocytotic pathways, indicating that a 
genetic LDL uptake pathway distinct from the classic LDL 
receptor exists in this animal model for FH. We cannot exclude 
the possibilities that either the loss of the classic LDL receptor 
resulted in an up-regulation of an alternate LDL binding sites 
or that the profoundly elevated LDL concentrations induced 
suppression of genetically distinct LDL binding sites. However, 
the physiologic implications of the residual LDL binding to FH 
hepatic membranes are at least as intriguing as the anticipated 
attenuated binding. 
Finally, the observation of normal activity of the rate-limiting 
enzyme of cholesterol biosynthesis, HMG-CoA reductase, in 
FH liver indicates that despite the loss of the classic LDL receptor, 
a steady state is ultimately reached in the hepatocyte to normalize 
cholesterol biosynthesis. Effective feedback regUlation ofHMG-
CoA reductase activity in the presence of an increased hepatic 
free and esterified cholesterol content suggests abnormalities in 
hepatic cellular cholesterol and cholesteryl ester compartmen-
tation and metabolism. The physiological effect of the loss of 
the classic LDL receptor and the residual LDL binding observed 
in these hepatic membranes on the altered hepatic cholesterol-
cholesteryl ester metabolism are purely speculative at the present 
time. 
In summary, hepatic membranes of receptor-negative FH 
homozygotes, demonstrate decreased specific binding of LDL. 
The residual specific, saturable recognition receptor may reflect 
LDL pathways unique to mature human liver and genetically 
distinct from the classic LDL pathway. The observed alterations 
in hepatic membrane binding parallel marked changes in hepatic 
cholesterol and cholesteryl ester content and normal HMG-
CoA reductase activity. Further inquiry into the relationship 
between hepatic lipoprotein binding sites and hepatocyte cho-
lesterol metabolism may shed additional insights on the regu-
lation of hepatic lipoprotein catabolism and biosynthesis. 
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